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 Urinary tract infections (UTI) are one of the most prevalent human 
diseases, with uropathogenic Escherichia coli (UPEC) being the primary cause of 
Gram-negative UTIs. Left untreated, bacteria can ascend from the bladder to the 
kidneys and eventually escape into the blood stream, causing a potentially lethal 
case of sepsis. With the shocking increase of antibiotic resistance, new 
treatments are necessary to combat these infections. UPEC are invasive bacteria 
that reside within host cells and can remain in a quiescent, metabolically inactive 
state that renders most current generation antibiotics useless. The primary aims 
of this dissertation are: 1. to identify host factors important for bacterial invasion 
and 2. determine how sensing of the bacteria by the innate immune system 
contributes to persistence or clearance of uropathogens. First, I investigated how 
plant-based natural products could be used to prevent UPEC invasion into host 
bladders. These natural products are often used as a part of traditional medicinal 
practices and may hold promising new methods of treatment for UTIs. The 
natural products tested successfully inhibited invasion into host cells in an in vitro 
model of UTI through inhibition of the focal adhesion kinase host factor. When 
tested in an in vivo model of UTI, invasion into bladder cells was also inhibited. 
Next, I investigate the role of the host protein histone deacetylase 6 (HDAC6) in 
an in vitro and in vivo model of UTI in both the somatic and hematopoietic 
  iv 
compartments. I discovered that although HDAC6 is a vital factor for host cell 
invasion in an in vitro model, in an in vivo HDAC6 knockout model bacteria were 
better able to invade the bladder mucosa at an early time point. Although there 
are elevated titers in HDAC6 knockouts very early, it is rapidly brought under 
control and remains near wild type levels through the examined time points. 
Investigation of neutrophils revealed both genotypes recruit similar numbers, 
though HDAC6 knockout neutrophils contain higher numbers of viable bacteria. 
Finally, I investigated the interplay between a bacterial motility organelle and its 
corresponding receptor in the host, Toll-Like Receptor 5, to elaborate how pro-
inflammatory signaling through the receptor altered the host’s ability to resolve a 
UTI. Overall, the sum of the research presented in this dissertation aims to 
identify the host factors important for bacterial invasion and persistence with the 
goal to eventually develop ways to manipulate the host to better treat UTIs and 
prevent recurrent UTIs.  
  
In memory of William F. Morgan
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Medical Consequences and Complications 
of Urinary Tract Infections 
Urinary tract infections (UTI) are one of the most prevalent bacterial 
diseases. Females are at a higher risk of contracting a UTI likely due to their 
shorter urethra [1]. In their lifetimes, 50% of women will contract at least one UTI 
and are at a 25% risk of contracting a second UTI within 6 months of the first [2, 
3]. In the United States alone, UTIs are annually responsible for 8 million 
infections, resulting in 8.1 million doctor’s visits and $2.14 billion in health care 
costs [4, 5]. In some cases, UTIs can ascend to the kidneys and may even 
escape into the blood stream leading to urosepsis, which carries a lethality rate 
of up to 40% [6]. 
The primary pathogen responsible for Gram-negative UTIs is 
uropathogenic Escherichia coli (UPEC), a subset of extraintestinal pathogenic 
Escherichia coli (ExPEC) [7]. These strains act as commensals in the intestinal 
flora without any apparent pathogenesis, but can cause diseases like meningitis 
and UTI once they escape the intestinal niche. Currently, the standard treatment 
for UPEC-caused UTIs is administration of oral antibiotics, but the effectiveness 
of this regimen is compromised by the intracellular lifestyle of UPEC, which 
protects the bacteria from antibiotics that cannot cross the host cell membrane, 
and the increasing prevalence of antibiotic resistance. 
 The intracellular lifestyle offers many advantages to UPEC including 
access to sequestered nutrients [8-10] and protection from antibiotics [11], 
immune cells, antibodies, and antimicrobial peptides. UPEC strains are 
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particularly well adapted for pathogenesis as they are able to invade and survive 
within a wide variety of host cells, both somatic and hematopoietic [12, 13]. 
Additionally, invasion of host cells can provide a niche that facilitates long-term 
survival and may contribute to recurrent infections [14, 15]. This concept 
becomes evident in mouse models where, despite sterilization of the urine 
through sustained administration of antibiotics, there is a failure to clear bladder-
resident bacteria [11]. 
 Recurrent UTIs are often due to reinfection with the same strain that 
caused the primary infection, and are likely contributing to the increase of 
antibiotic resistance due to the often repeat administration of the same antibiotics 
for recurrent infections [16-19]. ST131, a strain type of UPEC that carries multiple 
drug resistance genes, has recently seen global dissemination [20-22]. As these 
resistance genes are carried on plasmids, spread of antibiotic resistance to other 
bacterial strains is made disturbingly easy [23]. 
This trend emphasizes the need for new preventative measures as well as 
novel therapeutics. One possibility for new therapeutics is to target host factors 
that UPEC requires for invasion. By blocking invasion at the earliest stages of 
infection, the pathogen fails to gain entry to the host cell and may be stopped 
before any meaningful disease afflicts the patient. Another possibility is to modify 
the host immune response in such a way that promotes complete resolution of 




Important Factors of Bladder Cell Invasion 
Within the bladder, invasion can occur in any of the three distinct cell 
layers that comprise the urothelium: basal cells, intermediate cells, and 
superficial cells [24]. Basal and intermediate cells are undifferentiated cells that 
undergo rapid replication, differentiation, and repair of the luminal barrier upon 
damage [25]. In contrast, superficial cells are terminally differentiated and form a 
barrier that protects the underlying cells through a network of tight junctions and 
membrane-bound uroplakin plaques [26-28]. Exposure to bacteria can induce a 
basic antimicrobial defense in which the superficial cells are shed from the 
urothelium and expelled in the urine [29, 30]. While this can remove bacteria from 
the bladder, it opens up breaches in the urothelial barrier and gives rise to the 
possibility of invasion into the underlying cells [31]. Bacteria able to invade the 
underlying cells may contribute to recurrent infections. 
Unique to superficial cells are uroplakin plaques comprised of four major 
proteins including uroplakin Ia (UPIa), UPIb, UPII, and UPIIIa [32, 33]. These 
proteins form heterodimers consisting of UPIa/UPII and UPIb/UPIIIa, then into 
heterotetramers, and are finally assembled into hexameric complexes [34]. 
Uroplakin hexamers are stored in mature fusiform vesicles characterized by the 
presence of two uroplakin plaques [34, 35]. These large hexagonal structures 
can be as large as 1 µm in diameter and comprise up to 90% of the luminal 
surface [36]. As an integral part of the superficial cell membrane, uroplakins play 
important roles in normal bladder physiology, preventing urine reflux into the 
kidneys and assisting in maintenance of barrier function [28, 37, 38]. They are 
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also thought to play an integral role in bladder expansion and contraction, 
whereby additional uroplakin plaques are trafficked to the luminal membrane 
during expansion or endocytosed and trafficked to lysosomes for degradation 
during contraction of the bladder [39-41].  
One of the earliest steps of a UTI is adhesion between UPEC and the 
uroplakin-expressing superficial cells. This is accomplished through interaction 
between Type 1 pili on the bacteria and various host receptors [13, 30]. Type 1 
pili are adhesive organelles consisting of repeating structural units tipped by the 
FimH mannose-binding adhesin [42, 43]. FimH allows UPEC to bind 
mannosylated residues on the cell surface, and thereby resist removal by 
emptying of the bladder. This is accomplished through a catch-bond mechanism 
that enhances adhesion under shear flow conditions [44, 45]. UPEC lacking 
FimH are impaired at cell attachment and are quickly cleared by the host [46, 47]. 
Several specific membrane proteins on the superficial cell have been identified 
as targets of FimH including UPIa, α3 and β1 integrins, and Toll-Like Receptor 
(TLR) 4. 
Of the uroplakins, only UPIIIa has any appreciable intracellular region [48]. 
Therefore, it is likely that binding between UPIa and FimH does not directly signal 
to downstream factors to initiate invasion. However, binding of FimH to uroplakin 
plaques induced phosphorylation of the intracellular domain of UPIIIa and 
subsequently increased intracellular calcium concentration [49]. One hypothesis 
is that this cascade activates casein kinase II and promotes bacterial entry into 
host cells in vitro. It is also possible that signaling through UP complexes is not 
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required, and instead bacteria are endocytosed through natural cycling of 
uroplakin plaques. This scenario is problematic in that bacteria are significantly 
larger than uroplakin plaques, requiring the simultaneous uptake of multiple 
plaques. Another issue is that FimH-expressing bacteria are able to invade a 
wide variety of cells, while uroplakins are only expressed in the bladder and eye. 
A more ubiquitous receptor found in the bladder is α3 and β1 integrins [50-
52]. Previous work found that although FimH binds integrins α2, α6, and β4, only 
blocking the α3 and β1 subunits showed any significant reduction of invasion into 
bladder cells [53]. Further, the importance of signaling mediated by the 
intracellular tail of β1 integrin was indicated by the reduced invasion into host 
cells harboring mutations at critical residues that prevent phosphorylation. 
Interestingly, FimH did not associate with the binding pocket created by integrin, 
but rather bound to glycosylated residues on the integrins. FimH binding to 
integrins promoted clustering, which in turn led to focal adhesion kinase (FAK) 
autophosphorylation at tyrosine 397 (Y397). Phosphorylation of Y397 promotes 
binding by Src family kinases, which leads to phosphorylation of two additional 
residues and subsequent activation of FAK [54]. Activated FAK promotes actin 
nucleation and invasion by UPEC. Inhibition of either FAK or Src family kinases 
significantly attenuates the ability of UPEC to invade host cells [53]. Integrin 
receptors and downstream signaling events that lead to actin rearrangements are 
attractive targets for therapy as multiple pathogens, like Shigella, Salmonella, 
and Yersinia, are also dependent on actin cytoskeletal rearrangements for entry 
into host cells. 
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Another cytoskeletal component important for UPEC invasion are 
microtubules. Disruption of microtubule dynamics negatively impacts the ability of 
UPEC to invade host cells even though microtubules do not appear to associate 
with invading bacteria in the same way actin does [31, 55]. Current data suggest 
that microtubules do not directly interact with invading bacteria. Instead, kinesin, 
the motor protein that travels along the microtubules towards the plasma 
membrane, has been shown to be important for invasion. It is possible that 
kinesin is delivering factors important for invasion at the site of bacterial 
association [55]. 
 
Host Immune Response to Bacteria in the Bladder 
 Detection of bacteria within the bladder lumen is accomplished through a 
number of pattern recognition receptors (PRR) including TLR4 
(lipopolysaccharide), TLR5 (extracellular flagellin), and TLR11 (extracellular 
flagellin). Binding between FimH and TLR4 has been shown to induce nuclear 
factor kappa B (NFκB) signaling, which initiates critical immune signaling [56]. 
Mice that lack TLR4 have greater bacterial burdens within the bladder when 
compared to their wild type counterparts [56, 57]. Previous experimentation has 
also shown that mice lacking TLR5 or TLR11 also contain greater bacterial 
burdens in comparison to wild type mice [58, 59]. It would be easy to assume 
inflammation induced by these PRRs during bladder infections yields positive 
outcomes for the host, but elevated inflammation at early time points during UTI 
are associated with increased bacterial persistence, suggesting that not all 
inflammation is beneficial to the host [60]. Therefore, it is more appropriate to 
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consider inflammation in terms of quality rather than quantity. This distinction is 
evident in humans where polymorphisms in the TLR1, 2, 4, and 5 genes have 
been associated with either resistance or susceptibility to UTIs. These 
polymorphisms have also been associated with asymptomatic bacteriuria, which 
has been shown to be protective against pathogens that would otherwise cause 
symptomatic bacteriuria [61-65]. 
 Recruitment of immune cells to the bladder is initiated through bladder 
resident macrophages. Subsequent immune cells are recruited through a 
licensing mechanism in which circulating macrophages infiltrate the bladder and 
secrete tumor necrosis factor α (TNFα) [66]. TNFα induces resident 
macrophages to release CXCL2 and thereby recruit matrix metalloproteinase-9 
(MMP9)-expressing neutrophils to the sites of infection [66]. Without proper 
licensing, neutrophils fail to express MMP9 and are unable to enter the bladder. 
Neutrophils are the primary phagocyte during the early phases of infection, 
though they cede this role to macrophages as the immune response progresses 
[66]. 
 One notable feature of UTIs is how commonly they recur shortly after the 
primary infection, suggesting that an adaptive immune response is not fully 
developing to provide long-term protection to the host. RAG -/- mice, which lack 
mature B and T cells, demonstrate similar bacterial burdens on primary 
challenge, but increased (approximately 100 fold) bacterial burden on secondary 
challenge when compared to wild type mice [67, 68], indicating that it is possible 
to induce an adaptive response in experimental systems. The limited adaptive 
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response is developed between antigen presenting dendritic cells (DCs) and T 
cells, depletion of which negatively impacts the immune response to the 
secondary challenge, but not the primary [67]. Depletion of macrophages 
improves the adaptive immune response to secondary challenge, suggesting that 
macrophages are stymying adaptive immunity through phagocytosis of bacteria 
and subsequent antigen sequestration [67].  
 With antibiotic resistance rapidly spreading among UPEC strains coupled 
with the high risk of recurrence, the challenge facing modern medicine lies in 
identifying new therapeutics that can act either synergistically with, or 
independently of, currently prescribed antibiotics. Specifically, these therapies 
would target host factors and thereby reduce the development of resistance 
mechanisms by pathogens. Theoretical bipartite therapeutics would target both 
invasion and the immune response. These types of treatments could be taken 
prophylactically by high risk patients or simultaneously with another treatment to 
minimize reinfection of the bladder. 
 The research presented in the following chapters attempts to identify host 
factors that can be targeted similarly to how natural products derived from plants 
used in traditional medicines prevent invasion into the host cell. Next, we 
describe how regulation of post-translational modifications of microtubules are 
impacting bacterial invasion into host cells in an in vivo model as well as how this 
affects the immune system within the bladder. Finally, the role of TLR5, a PRR, 
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PLANT PHENOLICS ABLATE ACTIVATION OF FOCAL ADHESION 
 
KINASE AND INHIBIT BLADDER CELL INVASION BY 
 




Urinary tract infections (UTIs) are one of the most abundant human 
bacterial infections worldwide [1, 2]. Women are more susceptible to UTIs than 
men with nearly one third experiencing an acute UTI by the age of 24 and at 
least 25% of these individuals suffering a recurrent infection [2, 3]. The high rate 
of recurrence and the spread of antibiotic resistant uropathogens [4-6] are 
jeopardizing effective treatment options and pose an imminent global health risk 
[2]. 
Plants have long had a role in medicine, with herbs being components of 
traditional medicines used to treat pathogenic diseases like malaria [7], diarrhea 
[8], and respiratory diseases [9]. Modern medicine has recognized the usefulness 
of plant-based natural products for the basis of numerous therapeutics such as 
morphine as an analgesic [10] and Taxol as an anti-cancer compound [11]. 
Looking to plant-based traditional medicines as a basis for new treatments has 
revealed potential compounds for treating for heart disease [12, 13], cancer [14, 
15], and pathogens [16-20]. In popular culture, plant products are recommended 
as folk remedies, such as cranberry juice to treat UTIs [21]. Chemically, 
cranberry extracts contain a number of phenolic compounds that are biologically 
active in humans [22]. Recent studies have demonstrated that consumption of 
cranberry extracts is associated with a decreased incidence of recurrent urinary 
tract infections [23], likely by inhibiting adhesion to host cells through type 1 and 
P pili [24-28]. Cranberry extracts have also been associated with reduction in the 
risk of UTIs in postoperative patients [29, 30] and high-risk elderly populations 
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[31, 32]. In another study, investigators used compounds isolated from traditional 
seagrass-based medicines used to treat UTIs and found that many inhibited 
bacterial growth [33]. Along the lines of this study, traditional medicinal 
preparations from mandarin orange seeds were found to inhibit invasion into 
bladder epithelial cells, potentially by down regulation of 1 integrin [34]. 
Though the studies outlined are important steps in identifying new natural 
product-based treatments, many are very broad and generally do not investigate 
mechanism. Additionally, they identify interference with association between host 
and pathogen, but few investigate effects on invasion. They also tend to focus on 
a single pathogen as opposed to identifying broadly applicable invasive pathways 
used by multiple pathogens. This is a major oversight as invaded bacteria are 
able to remain hidden from the immune system and sequestered from antibiotics 
[35-37]. Specifically with UTIs, comparisons between primary and secondary 
infection strains has revealed an overwhelming incidence of reinfection with the 
same strains [38]. By using compounds that inhibit bacterial invasion, either 
prophylactically or as treatment for a UTI, the risk of reinfections could be 
reduced by preventing the creation of latent bacterial populations housed in host 
cells [39]. Therefore, we designed this study to investigate the anti-invasive 
mechanisms of multiple plant-based natural products that are commonly found in 








Materials and Methods 
Bacterial strains, cell lines and pharmacological inhibitors 
The clinical cystitis isolate UTI89 was grown statically in modified M9 
minimal medium (6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl, 0.1 mM CaCl2, 1 g/l 
NH4Cl, 1 mM MgSO4, 0.1% glucose, 0.0025% nicotinic acid, 0.2% casein amino 
acids, and 16.5 μg/ml thiamine) or Lysogeny Broth (LB; Difco) at 37C. 
AAEC185/pRI203, encoding the Yersinia invasin protein, was grown shaking in 
LB at 37C to stationary phage. Bacteria were diluted in M9 or LB to an OD600 of 
approximately 0.5 prior to use. Shigella flexneri (ATCC 12022) and Salmonella 
enterica serovar Typhimurium (SL1344) were grown shaking at 37C in LB 
overnight, then diluted 1:33 and grown for an additional 3.5 hours as previously 
described [40]. 
 5637 cells (ATCC HTB-9) were grown and maintained in RPMI-1640 
supplemented with 10% heat inactivated fetal bovine serum (Hyclone) in a 37C 
humidified incubator with 5% CO2. CAPE, resveratrol, EGCG, and catechin were 
purchased from Sigma-Aldrich, Biomol, or Cayman Chemical and dissolved in 
DMSO. Actinomycin D and cycloheximide were purchased from Sigma-Aldrich 
and dissolved in ethanol. 
 
Bacterial cell-association and invasion assays 
Bacterial invasion and cell-association assays were performed as 
described previously [41]. Briefly, confluent 5637 monolayers in 24-well tissue 
culture plates were pretreated with CAPE (25 µg/ml), resveratrol (100 µM), 
EGCG (25 µg/ml), or catechin (25 µg/ml) for 1 hour prior to infection. Controls 
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were treated with the carrier DMSO alone. BECs were infected with UTI89 or 
AAEC185/pRI203 at a multiplicity of infection (MOI) of approximately 15-25, or 
with S. flexneri or S. enterica at an MOI of 100. Tissue culture plates were 
centrifuged at 600 x g for 5 minutes to expedite and synchronize bacterial contact 
with the host cells. After 2 hours in the continued presence of the plant-based 
compound or carrier, sets of triplicate wells were washed 4 times with PBS-
Mg+2/Ca+2 and lysed in PBS containing 0.4% Triton-X 100.  These lysates were 
plated on LB agar plates to determine numbers of cell-associated bacteria. 
Alternatively, sets of triplicate wells were first treated with 100 µg/ml of 
gentamicin for 2 hours to kill extracellular bacteria prior to 4 washes PBS-
Mg+2/Ca+2 and lysis in 0.4% Triton-X 100. These lysates were plated to quantify 
the numbers of surviving intracellular bacteria. In experiments using S. enterica, 
host cells were infected for 30 min followed by 1-hour incubations in the 
presence of gentamicin prior to washes and host cell lysis. To assess the effects 
of host cell translation and transcription in the cell association and invasion 
assays, BECs were treated continuously with 26 µM cycloheximide, 5 µg/ml 
actinomycin D, or an equal volume of ethanol. Bactericidal activity of each 
compound was tested by treating bacteria in RPMI1640 + 10% heat inactivated 
FBS for 2 hours in the presence of DMSO or the compounds at the previously 








Western blot analysis 
Confluent BEC monolayers in 6-well plates were starved for serum 
overnight and then treated with CAPE (25 µg/ml), resveratrol (100 µM), EGCG 
(25 µg/ml), catechin (25 µg/ml), or carrier (DMSO) alone for 1 hour prior to 
infection with UTI89 (MOI~15). Plates were spun at 600 x g for 5 minutes and 
incubated 15 minutes. Wells were then washed with cold PBS-Mg+2/Ca+2, lysed 
in 50 mM Tris pH 7.4, 1 mM NaCl, 1% NP-40, 1X complete protease inhibitor 
(Roche), 1 mM PMSF, 1 mM NaF, and 0.4 mM orthovanidate, and processed for 
Western blot analysis. In other experiments, serum-starved BECs were infected 
with 100 µL of diluted bacterial suspension and incubated for up to 60 minutes 
before lysing the host cells in RIPA lysis buffer containing1X complete protease 
inhibitor, 1 mM PMSF, 1 mM NaF, and 0.4 mM orthovanidate at indicated time 
points. The primary antibodies used include mouse anti-FAK, mouse anti-p397 
(BD), and rabbit anti-p576 (Upstate). 
 
Kinexus “Kinetworks” multi-immunoblotting service 
5637 cells were seeded into 6 well plates and confluent in 24 hours. CAPE 
(25 µg/ml) or DMSO (Sigma-Aldrich) was added to each well.  The drug 
treatment was allowed to proceed for 1 hour.  UTI89 with an OD600 of 
approximately 0.5 was added to each well for 15 minutes.  The cells were 
washed 3 times with PBS2+ (PBS supplemented with Mg2+/Ca2+). The cells were 
then lysed with a buffer containing 50 mM Tris pH 7.4, 1 mM NaCl, 1% NP-40, 
1X Complete Protease Inhibitor (Roche Applied Sciences, Indianapolis, IN), 0.1 
µg PMSF (Elastin Products, Owensville, MO), 1 mM NaF (Sigma-Aldrich), 0.4 
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mM orthovanidate (Sigma-Aldrich), 5 µM leupeptin (Sigma- Aldrich), and 1 mM 
aprotinin (Roche Applied Sciences).  A BCA protein assay was used to 
determine protein content.  The protein concentration was diluted to 0.8 µg/µl 
and Kinexus 4X sample buffer was added.  The samples were shipped to 
Kinexus (Vancouver, Canada) for multi-immunoblotting analysis.   
 
Mouse infections 
Eight- to nine-week-old female CBA/JCrHsd mice (Harlan Laboratories) 
were inoculated via transurethral catheterization with 50 µl of a bacterial 
suspension (~107 CFU in PBS from a 24-hour static culture of UTI89) containing 
resveratrol (300 µM) or DMSO as previously described. Mice were killed 1-hour 
post infection, bladders were harvested aseptically, and quadrisected. Bladder 
pieces were treated with gentamicin (100 µg/ml in 1 mL PBS) for 30 minutes, 
washed twice in 1 ml PBS and lysed in 1 ml PBS containing 0.025% Triton X-
100. Total number of intracellular bacterial titers within the lysates was 
determined by plating serial dilutions on LB agar plates. A total of eleven mice 
from two independent experiments were tested for each treatment.  
 
Microscopy 
5637 cells were seeded into 24-well plates containing sterile 12 mm 
diameter coverslips for 24 hours until confluent.  DMSO, CAPE, EGCG, catechin, 
and resveratrol were added at the concentrations described previously and the 
cells were incubated for 3 hours.   After 3 hours, the cells were washed 3x with 
sterile PBS2+ and fixed with 2.5% paraformaldehyde.  The cells were stained with 
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Alexa568-conjugated phalloidin (1:40; Molecular Probes, Eugene, OR) to 
visualize F-actin. The slides were mounted with FluorSave (Calbiochem) and 
observed with an Olympus Fluoview series confocal microcope equipped with 
argon and krypton lasers providing excitation energy at 568 nm.  Images were 
captured using Olympus Fluorview software. 
 
Statistics 
Prism 6.07 (GraphPad Software) was used for all statistical tests. p values 
less than 0.05 were considered significant. 
 
Results 
Plant-based compounds inhibit host cell invasion by 
uropathogenic Escherichia coli 
We were interested in testing a variety of plant-based compounds in the 
context of a bladder infection model that allows us to quantify the ability of 
bacteria to associate with and invade host cells. To this end, we investigated the 
phenolic natural products caffeic acid phenethyl ester (CAPE), resveratrol, 
epigallocatechin gallate (EGCG), and catechin (Figure 2.1) in an in vitro model of 
urinary tract infections. These are phenolic compounds, much like many of the 
compounds found in cranberry extracts [22]. The bladder epithelial cell (BEC) line 
5637 was treated with the indicated compounds, and then infected with the 
cystitis strain UTI89. After 2 hours of incubation, the wells were washed to 
remove bacteria that remained unassociated with the host cells. Each well was 





Figure 2.1 Plant phenolics used in this study. Structure and plant source for (A) 
caffeic acid phenethyl ester (CAPE), (B) resveratrol, (C) catechin, and (D) (-) 




either intracellularly or extracellularly. Of the compounds tested, only resveratrol 
significantly reduced the number of bacteria associated with the host cells 
 (Figure 2.2A). Wells were further treated with gentamicin to eliminate 
extracellular bacteria, and the number of invaded bacteria were normalized to 
association. All of the compounds significantly inhibited the ability of UTI89 to 
invade host cells when compared to the DMSO control (Figure 2.2B). None of the 
compounds tested negatively impacted survival of UTI89 (Figure 2.3). These 
results suggest that the plant-based compounds are most likely inhibiting host 
factors required for invasion. 
 
Inhibition of invasion is independent of translation 
and transcription  
One potential explanation for how the plant-based compounds inhibit 
bacterial invasion includes the observation that CAPE can be an inhibitor of 
nuclear factor kappa B (NFκB), a transcription factor important for the immune 
response during infection [42]. In the context of UTIs, NFκB has not been 
investigated and warranted further pursuit as a possible mechanism of our 
observed phenotype. To determine if downstream NFκB-related factors were 
important for pathogen entry into host cells, we treated 5637 cells with 
actinomycin D (ActD), a transcription inhibitor, or cycloheximide (CHX), a protein 
synthesis inhibitor, and infected cells with UTI89 in an in vitro gentamicin 
protection assay. We hypothesized that if NFκB was involved in invasion through 
production of a host factor that facilitates invasion, either ActD or CHX would 




Figure 2.2 CAPE, resveratrol, and EGCG inhibit UTI89 invasion into a bladder 
cell line. (A) Cells were pretreated with the compounds for 2 hours, then infected 
with UTI89 in the presence of the compounds. Only resveratrol significantly 
inhibited association between host and pathogen. (B) Bacteria invaded into host 
cells normalized to DMSO control. CAPE, resveratrol, and EGCG significantly 
inhibited invasion. Bars indicate mean values ± standard error of the means 
(SEM) with n ≥ 3 independent experiments with 3 technical replicates per 





Figure 2.3 Catechin reduces growth of Salmonella while EGCG reduces growth 
of Shigella flexneri. UTI89, Salmonella Typhimurium, Shigella flexneri, and 
AAEC185/pRI203 were treated with DMSO or phenolic compounds for 2 hours, 
then titered. Colony forming units were enumerated and all values normalized to 
DMSO. Significant reductions in survival of Salmonella (a: p = 0.0393) and 
Shigella (b: p = 0.0368) were observed. Bars indicate mean values ± SEM with n 
= 3 independent experiments. p-values calculated by a one-sample t-test against 





synthesis did not significantly affect the ability of bacteria to associate with 
(Figure 2.4A) or invade (Figure 2.4B) host cells. This result demonstrates that 
CAPE’s ability to inhibit invasion is independent of NFκB and related transcribed 
immune factors, but rather inhibits an already present host factor necessary for 
invasion. 
 
Plant-derived phenolic compounds reduce phosphorylation 
of an activating FAK residue 
Since the plant-based compounds were acting on a factor already present 
in the cell, we hypothesized that the natural products were inhibiting post-
translational modifications. Previously published work found subapoptotic doses 
of CAPE can inhibit activation of focal adhesion kinase (FAK) [43]. FAK is a 
protein kinase that associates with integrins and is autophosphorylated at Y397 
by integrin clustering [44]. Activation of FAK by phosphorylation signals through 
many different pathways that can influence cell migration, survival, adhesion, and 
invasion [45-47]. Previously, we discovered that knockdown or knockout of FAK 
reduced bacterial invasion into 5637 bladder cells [48]. Similarly, inhibition of Src 
family kinases, which phosphorylate FAK at Y576 and Y577, reduces bacterial 
invasion into host cells [48]. 
To assess the level of phosphorylation of both FAK and other possible 
downstream targets, we used a phosphoprotein array from Kinexus to investigate 
phosphorylation status during infection and treatment with either DMSO or 
CAPE. Though phosphorylation levels in several proteins were different in CAPE-




Figure 2.4 Invasion into host cells is not dependent on RNA transcription or 
protein synthesis. (A) Bladder cells treated with actinomycin D (ACD) or 
cycloheximide (CHX), and then infected with UTI89, showed no significant 
differences in association 1-hour postinoculation. (B) Bladder cells treated with 
actinomycin D or cycloheximide showed no significant differences in invasion. 
Bars indicate mean values ± SEM with n = 3 independent experiments, each with 




of FAK Y576 (Figure 2.5A). Since the other natural products demonstrated 
similar phenotypes to CAPE, we were interested if they also inhibited 
phosphorylation of FAK Y576. We treated 5637 cells with DMSO, CAPE, EGCG, 
catechin, or resveratrol and infected them with UTI89. Probing infected cell 
lysates for phosphorylation of FAK Y397, the tyrosine autophosphorylated by 
integrin clustering [49], revealed some minor fluctuation between samples when 
compared to DMSO-treated controls (Figure 2.5B). However, probing for 
phospho-Y576 confirmed the dramatic reduction in phosphorylation observed by 
Kinexus when cells were treated with CAPE or resveratrol, and more modest 
reduction when treated with EGCG or catechin (Figure 2.5C). Interestingly, 
comparing intensities in Figure 2.5C with invasion in Figure 2.2B reveals a 
correlation between inhibition of phosphorylation of Y576 and invasion. These 
results suggest that inhibiting phosphorylation of FAK Y576 has downstream 
effects resulting in reduced invasion into the host cells. 
 
Plant-derived phenolic compounds alter the structure and  
morphology of filopodia and lamellipodia 
FAK has previously been shown to control cell motility and spreading 
through actin polymerization [45]. To investigate if the plant-based compounds 
altered cell morphologies, cells were incubated with DMSO, CAPE, catechin, 
EGCG, or resveratrol, fixed after 3 hours, and then visualized for actin. The most 
notable phenotype of treated cells was the morphological differences in 
lamellipodia, the actin skirt on the leading edge of a cell, and filopodia, actin 




Figure 2.5 FAK 576 phosphorylation is greatly reduced when bladder cells are 
treated with CAPE and resveratrol. (A) Phosphorylation of specific residues 
expressed as a percent of control. FAK phospho-Y576 (black bar) is the most 
downregulated of any of the residues when cells are treated with FAK. (B) FAK 
phospho-Y397 levels remain mostly unchanged under treatment with natural 
products. Overall FAK levels remain similar between treatments. (C) FAK 
phospho-Y576 is reduced when bladder cells are treated with CAPE, EGCG, 




DMSO (Figure 2.6A) were characterized by the presence of lamellipodia and a 
large number of regular filopodia. In comparison, cells treated with CAPE (Figure 
2.6B) showed no lamellipodia and very few, small filopodia. Catechin (Figure 
2.6C) and EGCG-treated cells (Figure 2.6D) still had lamellipodia, but filopodia 
were reduced in number and had a crooked, irregular appearance. Resveratrol 
(Figure 2.6E) greatly reduced both lamellipodia and filopodia. As normal actin 
dynamics are critical for host cell invasion by UPEC strains, this finding points to 
a potential role for inhibition of FAK Y576 resulting in altered actin nucleation that 
ultimately manifests as changes in the morphology of lamellipodia and filopodia. 
 
Plant-derived phenolic compounds can also inhibit invasion 
by a variety of intracellular pathogens 
We wanted to further investigate other invasive pathogens to assess the 
ability of the plant-based compounds to inhibit association or invasion. 5637 cells 
were challenged with Salmonella enterica serovar Typhimurium, Shigella flexneri, 
or AAEC185/pRI203, a K12 strain encoding the Yersinia invasin, in an in vitro  
model of invasion. With S. Typhimurium (Figure 2.7A), there was no notable 
change in association and only resveratrol significantly inhibited invasion (Figure 
2.7B). In the case of S. flexneri (Figure 2.7C) and AAEC185/pRI203 (Figure 
2.7E), EGCG and catechin increased association with host cells. When 
normalized to association, we found that all but catechin reduced S. flexneri 
(Figure 2.7D) invasion while all plant-based compounds reduced invasion by 
AAEC185/pRI203 (Figure 2.7F). Only treatment of Salmonella with catechin 





Figure 2.6 Plant-based compounds show altered morphologies of filopodia and 
lamellipodia revealed by staining for actin (white). Bladder cells treated with (A) 
DMSO show wild type morphologies of both filopodia and lamellipodia. Bladder 
cells treated with (B) CAPE show reduced numbers of small filopodia and no 
lamellipodia. (C) Catechin and (D) EGCG induce reduced numbers of filopodia 
and remaining filopodia have altered morphologies. (E) Resveratrol treatment 




Figure 2.7 Plant-based secondary metabolites reduce invasion by other 
pathogens in an in vitro model. (A) Salmonella association is not affected by any 
of the plant-based compounds, but (B) resveratrol does significantly reduce 
invasion into host cells. (C) Shigella association is higher with treatment of 
EGCG and catechin, but is not significant. (D) However, all compounds except 
catechin significantly reduce invasion. (E) AAEC185 expressing the Yersinia 
invasin associate at a significantly higher rate upon treatment with EGCG and 
catechin, but (F) all compounds significantly reduce host cell invasion. Bars 
indicate mean values ± SEM with n ≥ 3 independent experiments. p-values 
calculated by student’s t-test. 
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8.3% and 18.4% mean reduction, respectively (Figure 2.3). However, catechin 
did not reduce Salmonella invasion and EGCG treatment of Shigella actually 
increased association. These data demonstrate the robust ability of these 
compounds to inhibit invasion by a variety of pathogens. 
 
Resveratrol inhibits invasion of UTI89 into murine bladders 
Ultimately, the goal of this work was to identify if plant-based compounds 
could potentially be used to prevent or reduce bacterial burden in UTIs. Using an 
in vivo murine model of UTIs, we catheterized mice with UTI89 and either DMSO 
or resveratrol. Bladders were extracted, treated with gentamicin to kill 
extracellular bacteria, and the surviving intracellular bacteria were counted. 
Similar to what we had observed in vitro, bacterial numbers were significantly 
reduced in bladders treated with resveratrol (Figure 2.8). This result validates the 




The desperate need for new therapeutics to treat common bacterial 
infections gave rise to this study which looks at phenolic compounds found in 
food and drink. The activity of the chosen compounds was investigated in terms 
of the host instead of the bacteria, a strategy to reduce the opportunity for 
bacteria to develop resistance. This manuscript demonstrates that CAPE, 
resveratrol, and EGCG have anti-invasive properties in an in vitro model of UTI. 




Figure 2.8 Resveratrol inhibits bacterial invasion into bladders in an in vivo 
model of UTI. Bladders were catheterized with approximately 107 CFU of UTI89 
and either DMSO or resveratrol, extracted 1 hour later, and treated with 
gentamicin. Treatment with resveratrol significantly reduces invasion into bladder 
cells. Bars indicate median values with p-values calculated by Mann-Whitney U-




treatment with a transcription inhibitor or protein synthesis inhibitor did not reduce 
invasion. Rather, inhibition of invasion is correlated with a reduction in  
phosphorylation of FAK Y576. 
Phosphorylation of FAK Y397, the residue that allows for binding of Src 
family kinases and leads to phosphorylation of FAK Y576, remained largely 
consistent during treatment. Treatment of BECs with CAPE, resveratrol, EGCG, 
or catechin altered the number and morphology of filopodia and lamellipodia, 
both actin-dependent structures. These findings suggest that the plant based 
compounds are inhibiting activation of FAK by blocking phosphorylation of key 
residues and altering actin nucleation. This finding agrees with previous findings 
that normal actin dynamics are important for host cell invasion by UPEC [51, 52]. 
Previous work using human breast cancer cell lines found that treatment with 
resveratrol actually induced extension of filopodia and a reduction in FAK Y397 
phosphorylation, but only in cells expressing estrogen receptors [53]. This 
indicates that effects of these plant-based compounds are likely cell-specific. 
Expanding the scope of our pathogen to other invasive bacteria, we found that 
these compounds reduced invasion into host cells by Salmonella, Shigella, and a 
nonpathogenic K12 E. coli strain expressing the Yersinia invasin. The importance 
of actin dynamics during invasion has been previously implicated with each of 
these pathogens, agreeing with the inhibitory mechanism proposed in this 
manuscript [54-57]. When considering the role of filopodia in pathogenesis, 
previous work has shown that interaction with filopodia are important for invasion 
by Shigella and bacteria expressing the Yersinia invasin [58, 59]. Therefore, 
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disruption of filopodia would be expected to reduce invasion, which is what our 
results demonstrate. Importantly, we found that treatment of mouse bladders with 
resveratrol significantly reduced bacterial invasion in an in vivo model of UTI, 
providing valuable translational evidence of effectiveness. 
Overall, these results point to a role for the plant-based compounds to 
inhibit invasive pathogens by reducing phosphorylation of FAK Y576. This has 
the effect of reducing FAK activity, altering actin nucleation, and placing invasive 
pathogens at a disadvantage. In a host, these pathogens would be left exposed 
to antibiotics, antibodies, and immune cells when they otherwise would be 
protected in the intracellular niche. This is also an exciting finding as it could help 
reduce the number recurrent UTIs, a major issue that is likely contributing to the 
rise of antibiotic resistance [60, 61]. By targeting the host cell and reducing the 
quantity of antibiotics used during treatment, this strategy could slow the 
development of resistance. 
We demonstrated that co-catheterization with resveratrol reduced the 
number of invaded bacteria in mouse bladders, giving promising evidence that 
natural products can be developed for prophylactic and combination treatments. 
Future experiments should focus on the pharmacology of these compounds with 
the goal of adapting them into a form that would be present and active at relevant 
concentrations in target tissues. Ideally, the natural products would be in a stable 
form to make transport, ingestion, and adherence to a treatment plan by a patient 
as easy as possible.  
These results further validate traditional medicines in a time where 
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antibiotic resistance is spreading rapidly. As we look for new treatments, 




1. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract 
infection: Self-reported incidence and associated costs. Ann Epidemiol. 
2000;10(8):509-15. 
2. Foxman B, Brown P. Epidemiology of urinary tract infections: 
Transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 
2003;17(2):227-41. doi: 10.1016/s0891-5520(03)00005-9. 
3. Hooton TM. Recurrent urinary tract infection in women. Int J Antimicrob 
Agents. 2001;17:259-68. 
4. Goettsch W, van Pelt W, Nagelkerke N, Hendrix MGR, Buiting AGM, Petit 
PL, et al. Increasing resistance to fluoroquinolones in Escherichia coli from 
urinary tract infections in The Netherlands. J Antimicrob Chemother. 
2000;46:223-8. 
5. Williams DN, Sannes MR, Eckhoff AA, Peterson PK, Johnson JR, Román 
MS, et al. Antimicrobial resistance in Escherichia coli causing urinary tract 
infections in Costa Rica: A clinical dilemma. Int J Antimicrob Agents. 2003;21:79-
81. 
6. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin 
resistance in community- and hospital-acquired Escherichia coli urinary tract 
infections: A systematic review and meta-analysis of observational studies. BMC 
Infect Dis. 2015;15:545. doi: 10.1186/s12879-015-1282-4. PubMed PMID: 
26607324; PubMed Central PMCID: PMCPMC4660780. 
7. Ngarivhume T, van't Klooster CIEA, de Jong JTVM, Van der Westhuizen 
JH. Medicinal plants used by traditional healers for the treatment of malaria in the 
Chipinge district in Zimbabwe. J Ethnopharmacol. 2015;159:224-37. doi: 
10.1016/j.jep.2014.11.011. PubMed PMID: 25449454. 
8. Mishra A, Seth A, Maurya SK. Therapeutic significance and 
pharmacological activities of antidiarrheal medicinal plants mention in Ayurveda: 
A review. J Intercult Ethnopharmacol. 2016;5(3):290-307. 
9. Fratkin E. Traditional medicine and concepts of healing among Samburu 
pastoralists of Kenya. J Ethnobiol. 1996;16(1):63-97. 
  
41 
10. Wink M. Physiology of the accumulation of secondary metabolites with 
special reference to alkaloids. In: Constabel F, Vasil IK, editors. Cell Culture and 
Somatic Cell Genetics of Plants. 4. San Diego, CA: Academic Press; 1987. p. 17-
42. 
11. Hussain MS, Fareed S, Ansari S, Rahman MA, Ahmad IZ, Saeed M. 
Current approaches toward production of secondary plant metabolites. J Pharm 
Bioallied Sci. 2012;4(1):10-20. doi: 10.4103/0975-7406.92725. PubMed PMID: 
22368394; PubMed Central PMCID: PMCPMC3283951. 
12. Khalil MI, Sulaiman SA. The potential role of honey and its polyphenols in 
preventing heart diseases: A review. Afr J Tradit Complement Altern Med. 
2010;7(4):315-21. 
13. Bulotta S, Celano M, Lepore SM, Montalcini T, Pujia A, Russo D. 
Beneficial effects of the olive oil phenolic components oleuropein and 
hydroxytyrosol: Focus on protection against cardiovascular and metabolic 
diseases. J Transl Med. 2014;12:219. 
14. Henning SM, Wang P, Abgaryan N, Vicinanza R, de Oliveira DM, Zhang 
Y, et al. Phenolic acid concentrations in plasma and urine from men consuming 
green or black tea and potential chemopreventive properties for colon cancer. 
Mol Nutr Food Res. 2013;57(3):483-93. doi: 10.1002/mnfr.201200646. PubMed 
PMID: 23319439; PubMed Central PMCID: PMCPMC3600069. 
15. Wang W, Zhang X, Qin J-J, Voruganti S, Nag SA, Wang M-H, et al. 
Natural product ginsenoside 25-OCH3-PPD inhibits breast cancer growth and 
metastasis through down-regulating MDM2. PLoS One. 2012;7(7):e41586. doi: 
10.1371/journal.pone.0041586. PubMed PMID: 22911819; PubMed Central 
PMCID: PMCPMC3402429. 
16. Klančnik A, Možina SS, Zhang Q. Anti-Campylobacter activities and 
resistance mechanisms of natural phenolic compounds in Campylobacter. PLoS 
One. 2012;7(12):e51800. doi: 10.1371/journal.pone.0051800. PubMed PMID: 
23284770; PubMed Central PMCID: PMCPMC3524091. 
17. Ahmed AS, McGaw LJ, Eloff JN. Evaluation of pharmacological activities, 
cytotoxicity and phenolic composition of four Maytenus species used in Southern 
African traditional medicine to treat intestinal infections and diarrhoeal diseases. 
BMC Complement Altern Med. 2013;13:100. 
18. Pimentel RBdQ, da Costa CA, Albuquerque PM, Junior SD. Antimicrobial 
activity and rutin identification of honey produced by the stingless bee Melipona 
compressipes manaosensis and commercial honey. BMC Complement Altern 
Med. 2013;13:151. 
19. Takeuchi H, Trang VT, Morimoto N, Nishida Y, Matsumura Y, Sugiura T. 
Natural products and food components with anti-Helicobacter pylori activities. 
  
42 
World J Gastroenterol. 2014;20(27):8971-8. doi: 10.3748/wjg.v20.i27.8971. 
PubMed PMID: 25083070; PubMed Central PMCID: PMCPMC4112882. 
20. Njeru SN, Obonyo M, Nyambati S, Ngari S, Mwakubambanya R, Mavura 
H. Antimicrobial and cytotoxicity properties of the organic solvent fractions of 
Clerodendrum myricoides (Hochst.) R. Br. ex Vatke: Kenyan traditional medicinal 
plant. J Intercult Ethnopharmacol. 2016;5(3):226-32. doi: 
10.5455/jice.20160416122003. PubMed PMID: 27366347; PubMed Central 
PMCID: PMCPMC4927126. 
21. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Choodnovskiy I, Lipsitz LA. 
Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 
1994;271(10):751-4. 
22. Côté J, Caillet S, Doyon G, Sylvain J-F, Lacroix M. Bioactive compounds 
in cranberries and their biological properties. Crit Rev Food Sci Nutr. 
2010;50(7):666-79. doi: 10.1080/10408390903044107. PubMed PMID: 
20694928. 
23. Maki KC, Kaspar KL, Khoo C, Derrig LH, Schild AL, Gupta K. 
Consumption of a cranberry juice beverage lowered the number of clinical urinary 
tract infection episodes in women with a recent history of urinary tract infection. 
Am J Clin Nutr. 2016;103(6):1434-42. doi: 10.3945/ajcn.116.130542. PubMed 
PMID: 27251185. 
24. Singh I, Gautam LK, Kaur IR. Effect of oral cranberry extract (standardized 
proanthocyanidin-A) in patients with recurrent UTI by pathogenic E. coli: A 
randomized placebo-controlled clinical research study. Int Urol Nephrol. 2016:1-
8. 
25. Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE. 
Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary 
cultured bladder and vaginal epithelial cells. J Urol. 2007;177(6):2357-60. doi: 
10.1016/j.juro.2007.01.114. PubMed PMID: 17509358; PubMed Central PMCID: 
PMCPMC3684265. 
26. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, 
Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-
adhesion activity. Phytochemistry. 2005;66(18):2281-91. doi: 
10.1016/j.phytochem.2005.05.022. PubMed PMID: 16055161. 
27. Rafsanjany N, Senker J, Brandt S, Dobrindt U, Hensel A. In vivo 
consumption of cranberry exerts ex vivo antiadhesive activity against FimH-
dominated uropathogenic Escherichia coli: A combined in vivo, ex vivo, and in 
vitro study of an extract from Vaccinium macrocarpon. J Agric Food Chem. 
2015;63(40):8804-18. doi: 10.1021/acs.jafc.5b03030. PubMed PMID: 26330108. 
28. Hotchkiss AT, Jr., Nuñez A, Strahan GD, Chau HK, White AK, Marais JPJ, 
  
43 
et al. Cranberry xyloglucan structure and inhibition of Escherichia coli adhesion 
to epithelial cells. J Agric Food Chem. 2015;63(23):5622-33. doi: 
10.1021/acs.jafc.5b00730. PubMed PMID: 25973733. 
29. Foxman B, Cronenwett AEW, Spino C, Berger MB, Morgan DM. 
Cranberry juice capsules and urinary tract infection after surgery: Results of a 
randomized trial. Am J Obstet Gynecol. 2015;213(2):194 e1-8. doi: 
10.1016/j.ajog.2015.04.003. PubMed PMID: 25882919; PubMed Central PMCID: 
PMCPMC4519382. 
30. Vostalova J, Vidlar A, Simanek V, Galandakova A, Kosina P, Vacek J, et 
al. Are high proanthocyanidins key to cranberry efficacy in the prevention of 
recurrent urinary tract infection? Phytother Res. 2015;29(10):1559-67. doi: 
10.1002/ptr.5427. PubMed PMID: 26268913. 
31. van den Hout WB, Caljouw MAA, Putter H, Cools HJM, Gussekloo J. 
Cost-effectiveness of cranberry capsules to prevent urinary tract infection in long-
term care facilities: Economic evaluation with a randomized controlled trial. J Am 
Geriatr Soc. 2014;62(1):111-6. doi: 10.1111/jgs.12595. 
32. Caljouw MAA, van den Hout WB, Putter H, Achterberg WP, Cools HJM, 
Gussekloo J. effectiveness of cranberry capsules to prevent urinary tract 
infections in vulnerable older persons: A double-blind randomized placebo-
controlled trial in long-term care facilities. J Am Geriatr Soc. 2014;62(1):103-10. 
doi: 10.1111/jgs.12593. 
33. Ragupathi Raja Kannan R, Arumugam R, Anantharaman P. Chemical 
composition and antibacterial activity of Indian seagrasses against urinary tract 
pathogens. Food Chem. 2012;135(4):2470-3. doi: 
10.1016/j.foodchem.2012.07.070. PubMed PMID: 22980830. 
34. Vollmerhausen TL, Ramos NL, Dzung DTN, Brauner A. Decoctions from 
Citrus reticulata Blanco seeds protect the uroepithelium against Escherichia coli 
invasion. J Ethnopharmacol. 2013;150(2):770-4. doi: 10.1016/j.jep.2013.09.050. 
PubMed PMID: 24120518. 
35. Blango MG, Ott EM, Erman A, Veranic P, Mulvey MA. Forced resurgence 
and targeting of intracellular uropathogenic Escherichia coli reservoirs. PLoS 
One. 2014;9(3):e93327. doi: 10.1371/journal.pone.0093327. PubMed PMID: 
24667805; PubMed Central PMCID: PMCPMC3965547. 
36. Mysorekar IU, Hultgren SJ. Mechanisms of uropathogenic Escherichia coli 
persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A. 
2006;103(38):14170-5. 
37. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, et 
al. Differentiation and developmental pathways of uropathogenic Escherichia coli 
in urinary tract pathogenesis. Proc Natl Acad Sci U S A. 2004;101(5):1333-8. 
  
44 
38. Russo TA, Stapleton A, Wenderoth S, Hooton TM, Stamm WE. 
Chromosomal restriction fragment length polymorphism analysis of Escherichia 
coli strains causing recurrent urinary tract infections in young women. J Infect 
Dis. 1995;172(2):440-5. 
39. Horsley H, Malone-Lee J, Holland D, Tuz M, Hibbert A, Kelsey M, et al. 
Enterococcus faecalis subverts and invades the host urothelium in patients with 
chronic urinary tract infection. PLoS One. 2013;8(12):e83637. doi: 
10.1371/journal.pone.0083637. PubMed PMID: 24363814; PubMed Central 
PMCID: PMCPMC3868479. 
40. Knodler LA, Finlay BB, Steele-Mortimer O. The Salmonella effector protein 
sopb protects epithelial cells from apoptosis by sustained activation of Akt. J Biol 
Chem. 2005;280(10):9058-64. doi: 10.1074/jbc.M412588200. PubMed PMID: 
15642738. 
41. Lewis AJ, Dhakal BK, Liu T, Mulvey MA. Histone deacetylase 6 regulates 
bladder architecture and host susceptibility to uropathogenic Escherichia coli. 
Pathogens. 2016;5(1). doi: 10.3390/pathogens5010020. PubMed PMID: 
26907353; PubMed Central PMCID: PMCPMC4810141. 
42. Natarajan K, Singh S, Burkey TR, Jr., Grunberger D, BAggarwal BB. 
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of 
nuclear transcription factor NFκB. Proc Natl Acad Sci USA. 1996;93:9090-5. 
43. Weyant MJ, Carothers AM, Bertagnolli ME, Bertagnolli MM. Colon cancer 
chemopreventive drugs modulate integrin-mediated signaling pathways. Clin 
Cancer Res. 2000;6:949-56. 
44. Cooper LA, Shen T-L, Guan J-L. Regulation of focal adhesion kinase by 
its amino-terminal domain through an autoinhibitory interaction. Mol Cell Biol. 
2003;23(22):8030-41. doi: 10.1128/mcb.23.22.8030-8041.2003. 
45. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: In 
command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6(1):56-68. doi: 
10.1038/nrm1549. PubMed PMID: 15688067. 
46. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO. Src-
mediated phosphorylation of focal adhesion kinase couples actin and adhesion 
dynamics to survival signaling. Mol Cell Biol. 2004;24(18):8113-33. doi: 
10.1128/MCB.24.18.8113-8133.2004. PubMed PMID: 15340073; PubMed 
Central PMCID: PMCPMC515031. 
47. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman 
LM, et al. Biological significance of focal adhesion kinase in ovarian cancer. Am J 
Pathol. 2004;165(4):1087-95. doi: 10.1016/s0002-9440(10)63370-6. 
48. Eto DS, Jones TA, Sundsbak JL, Mulvey MA. Integrin-mediated host cell 
  
45 
invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog. 
2007;3(7):e100. doi: 10.1371/journal.ppat.0030100. PubMed PMID: 17630833; 
PubMed Central PMCID: PMCPMC1914067. 
49. Kornberg L, Earp HS, Parsons JT, Schaller MD, Juliano RL. Cell adhesion 
or integrin clustering increases phosphorylation of a focal adhesion-associated 
tyrosine kinase. J Biol Chem. 1992;267(33):23439-42. 
50. Skau CT, Waterman CM. Specification of architecture and function of actin 
structures by actin nucleation factors. Annu Rev Biophys. 2015;44:285-310. doi: 
10.1146/annurev-biophys-060414-034308. PubMed PMID: 26098516. 
51. Wang H, Liang F-X, Kong X-P. Characteristics of the phagocytic cup 
induced by uropathogenic Escherichia coli. J Histochem Cytochem. 
2008;56(6):597-604. doi: 10.1369/jhc.2008.950923. PubMed PMID: 18347076; 
PubMed Central PMCID: PMCPMC2386762. 
52. Sheehan KB, Martin M, Lesser CF, Isberg RR, Newton IL. Identification 
and characterization of a candidate Wolbachia pipientis type IV effector that 
interacts with the actin cytoskeleton. MBio. 2016;7(4):e00622. doi: 
10.1128/mBio.00622-16. PubMed PMID: 27381293. 
53. Azios NG, Dharmawardhane SF. Resveratrol and estradiol exert disparate 
effects on cell migration, cell surface actin structures, and focal adhesion 
assembly in MDA-MB-231 human breast cancer cells. Neoplasia. 2005;7(2):128-
40. doi: 10.1593/neo.04346. PubMed PMID: 15802018; PubMed Central PMCID: 
PMCPMC1501122. 
54. Shi J, Casanova JE. Invasion of host cells by Salmonella typhimurium 
requires focal adhesion kinase and p130Cas. Mol Biol Cell. 2006;17:4698-708. 
doi: 10.1091/mbc.E06. 
55. Benedek O, Nagy G, Emődy L. Intracellular signalling and cytoskeletal 
rearrangement involved in Yersinia pestis plasminogen activator (Pla) mediated 
HeLa cell invasion. Microb Pathog. 2004;37(1):47-54. doi: 
10.1016/j.micpath.2004.04.001. PubMed PMID: 15194160. 
56. Tran Van Nhieu G, Caron E, Hall A, Sansonetti PJ. IpaC induces actin 
polymerization and filopodia formation during Shigella entry into epithelial cells. 
EMBO J. 1999;18(12):3249-62. 
57. Davidson AC, Humphreys D, Brooks ABE, Hume PJ, Koronakis V. The arf 
GTPase-activating protein family is exploited by Salmonella enterica Serovar 
Typhimurium to invade nonphagocytic host cells. MBio. 2015;6(1):e02253. doi: 
10.1128/mBio.02253-14. PubMed PMID: 25670778; PubMed Central PMCID: 
PMCPMC4337568. 
58. Romero S, Grompone G, Carayol N, Mounier J, Guadagnini S, Prevost M-
  
46 
C, et al. ATP-mediated Erk1/2 activation stimulates bacterial capture by filopodia, 
which precedes Shigella invasion of epithelial cells. Cell Host Microbe. 
2011;9(6):508-19. doi: 10.1016/j.chom.2011.05.005. PubMed PMID: 21669399; 
PubMed Central PMCID: PMCPMC4425278. 
59. Young VB, Falkow S, Schoolnik GK. The invasin protein of Yersinia 
enterocolitica: Internalization of invasin-bearing bacteria by eukaryotic cells is 
associated with reorganization of the cytoskeleton. J Cell Biol. 1992;116(1):197-
207. 
60. Al-Mayahie SMG, Al Kuriashy JJH. Distribution of ESBLs among 
Escherichia coli isolates from outpatients with recurrent UTIs and their 
antimicrobial resistance. J Infect Dev Ctries. 2016;10(6):575-83. doi: 
10.3855/jidc.6661. PubMed PMID: 27367005. 
61. Ejrnaes K, Sandvang D, Lundgren B, Ferry S, Holm S, Monsen T, et al. 
Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples 
collected before and after pivmecillinam or placebo treatment of uncomplicated 
community-acquired urinary tract infection in women. J Clin Microbiol. 
2006;44(5):1776-81. doi: 10.1128/JCM.44.5.1776-1781.2006. PubMed PMID: 







HISTONE DEACETYLASE 6 REGULATES BLADDER 
 
ARCHITECTURE AND HOST SUSCEPTIBILITY 
 
TO UROPATHOGENIC ESCHERICHIA COLI 
 
 
Copyright © MDPI, Pathogens, 5, 20, 2016, 1-11, doi: 
10.3390/pathogens5010020 
 





































TOLL-LIKE RECEPTOR 5 SIGNALLING PROMOTES  
 
PERSISTANCE BY UROPATHOGENIC 
 
ESCHERICHIA COLI IN THE  
 




Urinary tract infections (UTIs) are one of the most prevalent bacterial 
infections to afflict humans [1]. Uropathogenic Escherichia coli (UPEC) are the 
primary causative agent. Even when the patient is cleared of UTI symptoms 
through the use of antibiotics, there is a 25% chance of reinfection within 6 
months of the primary infection [2]. This recurrent infection is disproportionately 
due to infection with the same strain as the primary infection, suggesting that the 
bacteria responsible for the primary infection are often not sufficiently cleared by 
the combination of antibiotics and the host immune system [3, 4]. 
Detection of UPEC within the bladder is mediated by pattern recognition 
receptors including Toll-Like Receptor (TLR) 4 and TLR5 [5, 6]. Mice lacking 
TLR4 were previously shown to have higher bladder titers during UTI, suggesting 
that clearance of UTIs is in part reliant on TLR4-mediated proinflammatory 
signaling [5, 7]. Inflammatory signaling mediated through TLR5 is likely more 
nuanced, as demonstrated in published research showing that flagella can 
induce strain-dependent inflammation in both zebrafish and mice [8]. 
Flagella are a bacterial motility organelle that have been shown to play a 
role in kidney colonization during UTI [9, 10]. In mice, flagella are detected by 
TLR5 and TLR11, though TLR11 is a pseudogene in humans that is not 
expressed [11]. In epithelial cells, binding between TLR5 and flagella activates 
nuclear factor kappa B (NFκB) and induces pro-inflammatory cytokines like IL-1β 
and IL-8 [12, 13]. Generally, detection of bacteria within the urinary tract triggers 
activation of the host innate immune system, which includes activation of bladder 
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resident macrophages leading to the recruitment of circulating macrophages [14]. 
In turn, recruited macrophages license the recruitment of neutrophils, which are 
the primary phagocyte at early time points. As the infection progresses, 
macrophages take a more prominent role in combating UPEC as neutrophils 
numbers are reduced within the bladder. 
Despite the influx of innate immune cells, there does not appear to be an 
appreciable role for the adaptive immune system during the primary infection as 
mice lacking T cells and B cells have similar bacterial burdens during UTI [15, 
16]. Investigation into the development of adaptive immunity during UTI has 
suggested that this may be due to antigen sequestration by macrophages, which 
prevent proper presentation to adaptive immune cells [16]. 
Proper signaling by pattern recognition receptors has been shown to be 
important for clearance of UTIs. Blocking recruitment of neutrophils, ablation of 
macrophages or improper TLR4 signaling has been demonstrated to increase 
bacterial burdens in the bladder, likely due to a reduced proinflammatory 
response [5, 14, 17]. However, the presence of high levels of proinflammatory 
cytokines has been shown to be a risk factor for bacterial persistence in the 
bladder [17]. 
The overall bladder immune response appears to be inadequate under 
normal conditions. Blocking recruitment of neutrophils or macrophages to the 
bladder has either no or only modest increases in titers and, in the case of 
macrophages, may improve outcomes during a secondary infection. Adaptive 
immune cells also seem to have a modest effect on the secondary infection. 
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Reducing proinflammatory cytokines increases acute titers, but increasing 
proinflammatory cytokines increases the likelihood of persistence within the 
bladder. These seemingly contradictory findings can be reconciled if the quality 
of inflammation is considered instead of the quantity. With this framing of the 
host-pathogen interaction during UTIs, inflammation is not a matter of too much 
or too little, but rather the proper tuning of the immune system for complete 
clearance of the pathogen. This chapter investigates the role of TLR5-mediated 
signaling during UTIs and presents evidence that signaling through TLR5 
induces a quality of inflammation that promotes bacterial persistence. 
 
Materials and Methods 
Bacterial and mouse strains 
The pyelonephritis strain CFT073 and cystitis strain F11 were obtained 
from the lab of Harry Mobley at the University of Michigan. CFT073ΔfliC::kanR 
and F11ΔfliC::kanR were generated and described previously [8]. Bacterial 
cultures for bladder catheterizations were grown from frozen stocks in 20 mL 
Lysogeny Broth (LB; Fisher Scientific) or M9 minimal media static cultures at 
37°C. C57BL/6J and TLR5 knockout mice (TLR5 -/-) in the C57BL/6J 
background were obtained from The Jackson Laboratories. All mice used were 
between 7-10 weeks old. Mice were genotyped using primers and thermocycler 
protocols described by The Jackson Laboratories. Animals were used in 
accordance to protocols approved by the Animal Studies Committee at the 





Mice were anesthetized by isoflurane inhalation and catheterized with 
approximately 107 CFU of bacteria in a volume of 50 µL PBS. Mice were then 
returned to their cages to recover. At the indicated time points, mice were killed 
by cervical dislocation under anesthesia. Bladders and kidneys were aseptically 
removed, quartered, and placed in microcentrifuge tubes with PBS. Bladders and 
kidneys were homogenized using 3.2 mm stainless steel balls and a 
BulletBlender Storm 24 tissue homogenizer (NextAdvance). Serial dilutions of 
tissue homogenates were plated on LB agar and counted to enumerate bacteria. 
Data was collected from 2 or more independent assays. 
 
RNA sequencing and analysis 
Wild type and TLR5 -/- mice were infected with F11 and the infection was 
allowed to proceed until the indicated time points. Mice were killed by cervical 
dislocation under anesthesia and bladders extracted. Bladders were processed 
for RNA using either the Norgen Total RNA Isolation Kit (Norgen Biotech) or the 
GenElute Total RNA Isolation Kit (Sigma) according to the manufacturer’s 
protocol. RNA was submitted to the University of Utah High Throughput 
Genomics Core and libraries were prepared using RiboZero treatment. 
Sequencing was performed with Illumina TruSeq Stranded RNA-seq in 50 single-
end cycles. Sequences were analyzed with assistance from the University of 
Utah Bioinformatics Core. Pathways were investigated using Qiagen Ingenuity 





Prism 6.07 (GraphPad Software) was used for statistical testing in all 




TLR5 -/- mice are more resistant to UTIs 
Though TLR5 -/- mice lack one of their extracellular flagellin receptors, 
they maintain the presence of TLR11 (another extracellular flagellin receptor) and 
NLRC4 (an intracellular flagellin receptor). We hypothesized that without a full 
complement of flagellin receptors, mice would be less able to contain a urinary 
tract infection. To test this, we catheterized wild type (WT) and TLR5 -/- mice with 
the F11 cystitis strain and extracted bladders and kidneys 1 or 5 days later. At 1-
day postinoculation, WT and TLR5 -/- bladder titers were similar between the 
genotypes while kidneys showed significantly reduced titers in TLR5 -/- mice 
(Figure 4.1A). At 5-days postinoculation, we found that TLR5 -/- mice had 
significantly reduced titers in both the bladder and kidney when compared to wild 
type mice (Figure 4.1B). To confirm that this phenotype was not strain-specific, 
we repeated the experiment with the CFT073 pyelonephritis strain and 
enumerated titers at 5-days postinoculation. Though the magnitude of the 
difference was more modest, we found that TLR5 -/- bladder and kidney titers 
were significantly reduced in comparison to wild type (Figure 4.1C). This 
demonstrates that TLR5 -/- mice are better able to combat bacterial persistence 





Figure 4.1 Bladder and kidney TLR5 increases susceptibility to infection by two 
different strains of UPEC. WT and TLR5 -/- mice were catheterized with F11 and 
bladders and kidneys titered (A) 1-day or (B) 5-days postinoculation. Bladders 
showed similar titers at 1 day, though kidneys had significantly reduced 
colonization in TLR5 -/- mice. (C) WT and TLR5 -/- mice were catheterized with 
CFT073 and bladders and kidneys titered at 5-days postinoculation. Titers were 
significantly lower in both bladder and kidneys of TLR5 -/- mice. n ≥ 8 mice 
catheterized in at least 2 independent experiments. Bars indicate median values. 
Significance calculated using a Mann-Whitney nonparametric U-test. p-values ≤ 






Reduced bacterial titers in TLR5 -/- is independent of flagellin 
Since TLR5 is a flagellin receptor, we hypothesized that TLR5 -/- mice 
infected with CFT073 lacking flagellin would no longer show lower titers than wild 
type mice. To test this, we infected WT and TLR5 -/- mice with the CFT073ΔfliC 
pyelonephritis strain lacking the fliC component of flagellin, and extracted their 
bladders and kidneys 5 days later. To our surprise, TLR5 -/- mice maintained 
lower titers in both bladder and kidneys when compared to wild type mice (Figure 
4.2A). Further, comparing CFT073 and CFT073ΔfliC infections in either wild type 
(Figure 4.2B) or TLR5 -/- (Figure 4.2C) mice revealed no significant difference, 
suggesting that flagella may not play an important role in bladder pathogenesis, 
as has been previously published [9, 10], but rather TLR5-mediated signaling is 
promoting bacterial persistence within the urinary tract. 
 
RNA-seq results suggest differential involvement  
of the immune system in TLR5 -/- mice 
 Our previous experiments demonstrated that lack of the TLR5 receptor 
was beneficial to the host in the context of bladder and kidney infections, 
regardless of whether the bacteria actually produced flagella. One possibility to 
explain this difference is that knockout of TLR5 results in differential regulation of 
other TLRs. This phenotype has been observed with TLR7 and 8, in which 
knockout of TLR8 results in upregulation of TLR7 [18]. Another possibility is that 





Figure 4.2 CFT073 lacking flagella does not bring unity in titers between WT and 
TLR5 -/- mice. (A) WT and TLR5 -/- mice catheterized with CFT073ΔfliC showed 
significant differences in both bladder and kidney titers 5-days postinoculation 
with TLR5 -/- maintaining lower titers. When CFT073 and CFT073ΔfliC titers 
were compared between (B) WT or (C) TLR5 -/- mice, no significant difference 
was observed in either bladder or kidney titers. n ≥ 8 mice catheterized in at least 
2 independent experiments. Bars indicate median values. Significance calculated 




rather signaling occurs preferentially through existing TLRs. To gain a global 
perspective, we infected WT and TLR5 -/- mice with F11, isolated RNA from 
bladders at 1-  and 5-days postinoculation, and performed RNA-seq. 
At 1-day postinoculation, 36 genes were significantly downregulated while 
37 genes were significantly upregulated in TLR5 -/- when compared to WT. Many 
of these genes are involved in innate immunity and may hold clues to the 
mechanism behind TLR5 -/- phenotype (Table 4.1). For example, emr1 (F4/80), a 
marker of macrophages in mice, and lyz2 (lysozyme 2), an antimicrobial enzyme, 
were both upregulated in TLR5 -/- mice. Also observed is the upregulation of 
csf1r (macrophage colony-stimulating factor 1 receptor), which regulates 
macrophage differentiation and function. Notably missing from the list of 
differentially regulated genes was the presence of any cytokines normally 
associated with UTIs. In fact, the only cytokine with any significant differential 
regulation was IL-33. IL-33 has been found to be upregulated during UTIs 
through TLR4-signaling, though its role in the bladder has not been determined 
[19]. Additionally, with the exception of TLR5, no TLR demonstrated significantly 
different expression levels in TLR5 -/- mice. 
To gain better insight of the pathways that were differentially regulated 
between WT and TLR5 -/- mice, we used IPA software to analyze our RNA-seq 
data. Interestingly, pathways involving increased proliferation and differentiation 
of immune cells, inflammation, and immune cell trafficking were predicted to be 
significantly upregulated. Further, pathways representing myeloid and lymphoid 
cell death were predicted to be downregulated. These results suggest that in  
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Change KO1 KO2 KO3 KO4 KO5 WT1 WT2 WT3 WT4 WT5 
Tlr5 -1.500 
          Pydc3 -1.030 
          Per1 -0.803 
          Mmrn1 -0.744 
          Plk5 -0.740 
          Gm4956 -0.709 
          Per2 -0.666 
          Usp2 -0.666 
          Cys1 -0.661 
          Ide -0.660 
          Fgfbp3 -0.635 
          Olfr1033 -0.610 
          Hlf -0.596 
          Ttr -0.590 
          Lonrf3 -0.584 
          Kcnq5 -0.570 
          Reln -0.559 
          Dock3 -0.540 
          Csmd3 -0.525 
          Pcdh9 -0.520 
          Cdh19 -0.486 
          Fgl2 -0.474 
          Tsc22d3 -0.458 
          Snhg11 -0.457 
          Abca8a -0.450 
          Zbtb16 -0.447 
          Igf2 -0.428 
          Exph5 -0.428 
          Abca8b -0.425 
          Trpm8 -0.422 
          Hcn1 -0.405 
          Unc5c -0.392 
          Shank2 -0.381 
          Plagl1 -0.375 
          Tacc2 -0.329 
          Ssfa2 -0.286 
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Change KO1 KO2 KO3 KO4 KO5 WT1 WT2 WT3 WT4 WT5 
Itga6 0.252 
          
Btg1 0.260 
          
Prdx1 0.284 
          
Tmsb4x 0.318 
          
Csf1r 0.336 
          
Cadm3 0.346 
          
Maged2 0.361 
          
Pcolce 0.387 
          
Ctsc 0.387 
          
Mgst3 0.387 
          
St6gal1 0.390 
          
Pdia6 0.394 
          
H2-Aa 0.413 
          
Cfp 0.420 
          
Mcm7 0.425 
          
Arsi 0.431 
          
Krt15 0.432 
          
Cotl1 0.438 
          
Gm20390 0.439 
          
C1qa 0.460 
          
Nme2 0.468 
          
Ifi27l2a 0.475 
          
Lgmn 0.487 
          
Pf4 0.502 
          
Krt5 0.510 
          
Hcar2 0.517 
          
NA 0.524 
          
Adamts15 0.529 
          
Fbn1 0.538 
          
Il33 0.543 
          
Clec11a 0.546 
          
Lyz2 0.547 
          
Tyrobp 0.561 
          
Hist1h1b 0.597 
          
Hist1h1d 0.613 
          
Diras2 0.627 
          
Emr1 0.669 
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TLR5 -/- bladders there may be a larger and more sustained immune response 
than in WT bladders. 
At 5-days postinoculation, 11 genes were significantly downregulated and 
34 genes were significantly upregulated (Table 4.2). Though some immune-
related genes were identified as being differentially regulated, no clear trend 
emerged. Of note, nos1, a nitric oxide synthase gene, was significantly 
downregulated in TLR5 -/- while dll1, a gene expressed in maturing T-cells, was 
significantly upregulated. The use of IPA software also failed to identify any 
clearly relevant pathways that were differentially regulated between WT and 
TLR5 -/- bladders. These results suggest that by day 5, the expression profiles  
between WT and TLR5 -/- mice are similar despite the significantly lower 
bacterial titers in TLR5 -/- mice. 
 
Discussion 
 Flagella are important for bacterial motility and, in the context of UTIs, has 
been previously shown to promote bacterial ascension to the kidneys [9, 10]. 
Previous work using TLR5 -/- mice and CFT073 in a UTI model demonstrated 
that although titers in both the bladder and kidney were similar at early time 
points, at day 5 there was a significant resurgence of bacteria in both organs of 
knockout mice [6]. In our hands, repeating previously published experiments 
using the same strains of mice and bacteria (CFT073) demonstrated that 
bladders and kidneys of TLR5 -/- mice had significantly lower titers at 5 days 
postcatheterization (Figure 4.1C). We confirmed this finding using a second 
strain of bacteria (F11; Figure 4.1A and B) showing that our findings were not  
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Change KO1 KO2 KO3 KO4 KO5 KO6 WT1 WT2 WT3 WT4 WT5 
Pydc3 -1.277 
           
Tlr5 -1.108 
           
Ide -0.927 
           
Fgfbp3 -0.710 
           1500011- 
K16Rik 
-0.671 
           
Nos1 -0.649 
           
Rps24-ps3 -0.648 
           
Itpa -0.639 
           
Rps24 -0.577 
           
Clec2d -0.461 
           
Btaf1 -0.340 
           
Sqstm1 0.208 
           
Itfg3 0.233 
           
Dcaf7 0.259 
           
Kpna6 0.261 
           
Copa 0.284 
           
Uba1 0.290 
           
Supt5 0.291 
           
App 0.299 
           
Tnpo2 0.302 
           
Flii 0.303 
           
Snx33 0.303 
           
Dcaf5 0.308 
           
Tmem63a 0.339 
           
Os9 0.347 
           
Zfp652 0.348 
           
Trim28 0.371 
           
Lmna 0.382 
           
Actb 0.403 
           
Ldlr 0.410 
           
Lamb1 0.412 
           
Tesk1 0.414 
           
Ggcx 0.427 
           
Wdr6 0.440 
           
Loxl1 0.471 
           
Lamb2 0.471 








Change KO1 KO2 KO3 KO4 KO5 KO6 WT1 WT2 WT3 WT4 WT5 
Cbx4 0.484 
           Gpc3 0.486 
           Fbln2 0.491 
           Zfp574 0.527 
           Pigt 0.561 
           Flnc 0.607 
           Dll1 0.618 
           Cybrd1 0.623 
           Itgbl1 0.695 
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strain specific, but are instead due to the specific genotypes of the mice. 
This suggests that our phenotype is valid and that the previously 
published research may be due to procedural differences. Most notable is the 
catheterization procedure in which our mice were catheterized and returned to 
their cage for recovery while the previous authors catheterized their mice and 
sealed the urethra using collodion, eventually unsealing it after 6 hours. Also, 
comparisons with their data findings on 5 day titers in WT mice in which bacteria 
are cleared from the bladder are not repeated in the literature with C57BL6/J and 
CFT073. 
 Regardless, the ability to repeat the results found in TLR5 -/- mice with 
two strains of bacteria suggests a role for TLR5-mediated signaling that results in 
bacterial persistence. Our findings show that TLR5 detrimentally affects the 
ability of the host to clear bacteria from the urinary tract. Particularly surprising in 
these findings is the discovery that the lack of flagellin expression by bacteria did 
not equalize organ titers between WT and TLR5 -/- mice, contrary to our 
hypothesis. This suggests that TLR5-mediated sensing of flagellin is not 
important, but rather other TLR5-mediated functions in the presence of bacteria 
is important. This could be through freeing of TLR4 in the TLR4/5 heterodimer 
and altering the overall immune response [20]. 
RNA-seq results from bladders isolated at 1-day post-inoculation suggest 
that TLR5 is altering the recruitment of immune cells to the bladder as well as the 
quality of inflammation in a manner that prevents resolution of the infection. The 
only cytokine significantly upregulated in the TLR5 -/- bladder is IL-33, whose 
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role in UTIs has not been defined, but may be shaping the immune response to 
promote bacterial clearance. Pathway analysis of the results predicts that 
immune cell recruitment and survival is increased as well as inflammation, 
suggesting that the quality of the immune response in TLR5 -/- bladders is 
improved. 
At 5-days postinoculation, there are fewer differentially regulated genes 
and analysis fails to identify any pathways that could be contributing to our 
observed phenotype. An interpretation of this finding is that by day 5, WT and 
TLR5 -/- bladders are responding similarly to the infection despite WT bladders 
having significantly greater bacteria. More widely, similar expression profiles in 
the presence of significantly different levels of bacteria within the urinary tract 
could be reflective of the high recurrence of UTIs in human patients and the 
failure of the immune system to fully resolve the infection. 
Future experimentation will focus on validating and further exploring the 
RNA-seq data to elaborate the immune response at early time points. It is not 
surprising that an event occurring early in the infection does not impact bacterial 
titers until later, so elaborating that event is critical in identifying the mechanism 
behind the phenotype of lower titers in TLR5 -/-. Preliminarily, bladders will be 
infected, extracted at early time points, and fixed for sectioning. Hematoxylin and 
eosin staining will be used to assess gross inflammation as well as general 
localization of infiltrating immune cells. This infiltrate will be characterized using 
previously established methods in which bladders will be infected and extracted 
at different time points for analysis by flow cytometry and immunofluorescence 
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[21]. Specifically, antibodies against both myeloid and lymphoid populations will 
be used to characterize recruitment to the bladder during UTI.  
Macrophage-related genes were notably upregulated in the TLR5 -/- 
bladders at 1-day post infection, suggesting a role for macrophages. TLR5 -/- 
mice will be treated with clodrolonate liposomes to deplete macrophages and 
bladders will be catheterized. If macrophages are the key to bacterial clearance, 
the expectation is that macrophage-depleted TLR5 -/- mice will have elevated 
levels of bacteria in the bladders at day 5. It is also possible that the critical cell 
type to bacterial clearance is actually somatic rather than hematopoietic. By 
creating bone marrow chimeras (TLR5 -/- with WT bone marrow and vice versa), 
the critical cell compartment could be identified. 
IL-33 was the only cytokine whose expression was significantly altered in 
TLR5 -/- mice. The role of IL-33 in bladder infection will be further described by 
treating WT mice with IL-33 or treating TLR5 -/- mice with an IL-33 neutralizing 
antibody. If IL-33 is playing a critical role in bacterial clearance, the expectation is 
that IL-33-treated mice would show bladder titers more similar to TLR5 -/- mice. 
Likewise, neutralizing IL-33 in TLR5 -/- mice would cause bladder titers to 
resemble WT mice. 
Findings from these experiments could suggest new clinical treatments 
with the goal to fully resolve UTIs in patients. Incomplete resolution of UTIs is 
likely leading to recurrence and, therefore, spread of antibiotic resistance through 
repeated use [3, 22]. Development of new therapies could give new life to 
existing treatments and slow the development of resistance mechanisms within 
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UPEC by manipulating the host immune response. 
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 The prevalence of UTIs, high rates of recurrence, and spread of antibiotic 
resistance amongst UPEC creates a dire global health condition. Failure to 
properly treat UTIs raises the risk of renal scaring and urosepsis, particularly in 
pediatric and elderly patients. Therefore, new treatment methods must be rapidly 
identified and verified to avoid total therapeutic failure. The findings presented 
within this body of work demonstrate that targeting different stages of UTI may 
lead to positive patient outcomes. In conjunction with standard antibiotic 
treatments, these combination therapies may give physicians the edge. 
 Since invasion by UPEC is necessary for initiation and continuation of 
pathogenesis, the host-based mechanisms required for invasion provide 
therapeutic targets. To this end, Chapters 2 and 3 investigated how manipulation 
of the cytoskeleton in host cells could impact invasion during a UTI. Chapter 2 
investigated the effect of common plant phenolic compounds on the ability of 
UPEC to invade host cells. In our in vitro model of UTI we found that CAPE and 
resveratrol significantly inhibited invasion into host cells. When we tested these 
findings in an in vivo model using resveratrol, we were successfully able to 
recapitulate our in vitro results. We pursued these findings and discovered that 
treatment with the plant phenolic compounds were correlated with reducing 
activating phosphorylation event of FAK. This was observed morphologically as 
the BECs qualitatively demonstrated altered filopodia and lamellipodia, both 
actin-dependent structures. Likewise, we found invasion by Shigella flexneri, 
Salmonella Typhimurium, and a K12 strain expressing the Yersinia invasin could 
be inhibited by our plant phenolic compounds. This finding demonstrates the 
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usefulness of plant phenolic compounds in the prevention of disease, especially 
as the plant compounds are commonly consumed by humans. Further work 
would characterize other pathogens that may be susceptible to these compounds 
as well as similar plant-derived compounds. Ideally, diets could be “prescribed” 
for at-risk populations to minimize disease. 
 Chapter 3 focused on another part of the cytoskeleton: the microtubules. 
Previous work found that inhibiting HDAC6, which deacetylates microtubules, 
significantly reduced invasion in an in vitro model of UTI. We extended these 
findings into an HDAC6 -/- mouse line and found that while MEFs derived from 
the knockout mice were resistant to invasion, the mice themselves were actually 
more susceptible to invasion in an in vivo model of UTI, though titers normalized 
between WT and HDAC6 -/- as early as 6 hours postinoculation. We identified 
that HDAC6 -/- bladders had altered physiologies with greater maximum 
capacities and also had thicker muscle layers. These results suggest that 
HDAC6 is involved in the development of normal bladder architecture and that 
the abnormal bladder physiology contributes in some part to the higher invasion 
rates. 
Neutrophils recruited to bladder at early time points contained greater 
numbers of bacteria. The phenotype observed in HDAC6 -/- neutrophils may be 
due to slower recruitment to the bladder, giving less time for clearance when we 
assayed their bacterial content. Higher titers within the neutrophils may also be 
due to slower killing. It is also possible that the elevated titers found in HDAC6 -/- 
bladders are due to increased phagocytosis of bacteria and the urothelium does 
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not play a major role in the phenotype. These findings better describe how 
HDAC6 is involved in the bladder, though it does not provide a clear path for 
treatment. Further investigation of posttranslational modifications of microtubules 
and their associated motors may provide clearer target to combat bacterial 
invasion into host cells. 
 Finally, Chapter 5 looked at how persistence within the bladder was 
impacted by TLR5-mediated detection of bacterial flagellin. We had hypothesized 
that TLR5 -/- mice would be more susceptible to bacteria, but instead discovered 
that bacterial titers were lower in both the bladder and kidney at 5 days. This was 
not strain-specific, as another UPEC strain showed a similar phenotype in the 
bladder. TLR5 is canonically identified as a receptor of bacterial flagella, though 
using UPEC strains lacking flagella recapitulated bacterial quantities when wild 
type UPEC strains were used in either WT or TLR5 -/- mice. This may reflect 
TLR5 detecting an uncharacterized bacterial antigen. RNA-seq of samples 1 day 
postinoculation revealed that that there were strong associations with pathways 
related to immune cell infiltration, differentiation, and survival in TLR5 -/- 
bladders. We also observed a number of macrophage-associated genes 
upregulated in TLR5 -/- bladders. At 5 days, no clearly differentially regulated 
pathways were identified, suggesting that WT and TLR5 -/- bladders are acting 
similarly, despite WT bladders harboring significantly greater numbers of 
bacteria. This suggests that TLR5-induced inflammation places the host at a 
disadvantage for bacterial clearance and presents a tantalizing target. By 
blocking signaling through TLR5, bacterial persistence could be reduced. The 
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immune signaling revealed by the RNA-seq data suggests that potentially 
administering IL-33 could promote a better quality of immune recruitment and 
promote bacterial clearance. 
 The goal of this work was to identify host factors that could be targeted to 
prevent or treat UTIs. Targeting host factors is potentially less likely to generate 
resistance mechanisms in pathogens and, in combination with traditional 
antibiotics, could reduce the recurrence rate in patients. Through preventing 
invasion into the bladder through targeting of cytoskeletal components, bacteria 
can be stymied at one of the earliest stages of infection. Later stages of infection 
could be better resolved through manipulation of the host immune response by 
ensuring a better quality of inflammation. Together, these therapies could bring 
the startling rise of antibiotic resistant UPEC under control and reduce disease 
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